Australia MPS-III (Sanfilippo Syndrome) Drugs Market Report 2023 to 2030

Australia MPS-III (Sanfilippo Syndrome) Drugs Market Analysis

$ 3999

Australia MPS-III (Sanfilippo Syndrome) drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for MPS-III (Sanfilippo Syndrome) drugs is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global MPS-III (Sanfilippo Syndrome) drugs market.

ID: IN10AURD099 CATEGORY: Rare Diseases GEOGRAPHY: Australia AUTHOR: Sakshi Mantri

Buy Now

Australia MPS-III (Sanfilippo Syndrome) Drugs Market Analysis Summary

Australia MPS-III (Sanfilippo Syndrome) Drugs Market is valued at around $7.44 Mn in 2022 and is projected to reach $15.61 Mn by 2030, exhibiting a CAGR of 9.7% during the forecast period 2023-2030.

Mucopolysaccharidosis type III (MPS III) also called Sanfilippo syndrome is a hereditary metabolic disorder brought on by a lack of or an issue with specific enzymes required to degrade compounds called glycosaminoglycans (GAG). It is a neurodegenerative disease with seizures, hyperactivity, liver and spleen enlargement, severe diarrhoea or constipation, and tonsils and adenoid enlargement as symptoms. Sanfilippo syndrome has no known, accepted treatment. However, there are various (some conventional, some unique) treatment options for Sanfilippo syndrome, including hematopoietic stem cell transplantation, enzyme replacement therapy, the use of pharmacological chaperones, and gene therapy. The effectiveness of hematopoietic stem cell transplantation, which involves the transplants, was greatly questioned due to its potential to provide neurological advantages and safety. Enzyme replacement therapy (ERT) clinical studies are now being conducted to treat Sanfilippo syndrome MPS IIIA (intrathecal) and MPS IIIB (intravenous). Furthermore, the same will begin for Gene therapy. The most practical method for correcting genes is gene therapy, despite its extreme complexity. Another difficulty with the treatment is the need to implant the healthy gene into hundreds of millions of cells that already have the faulty gene. The market size for Sanfilippo syndrome will further increase with the introduction of new treatments for the condition, including SLS-005 (trehalose), Lysogene (LYS-SAF302), Tralesinidase alfa (BMN 250), and others. Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global MPS-III (Sanfilippo Syndrome) drugs market.

Market Dynamics

Market Drivers

Improvement in diagnostics methodologies, Increase in understanding of the disease, increase in healthcare spending across the world, increase in research and development activities, patient support and advocacy programmes and launch of new therapies like Enzyme replacement therapy, gene therapy CRISPR-Cas9 and substrate reduction therapy all act as a market growth drivers.

The launch of emerging therapies such as SLS-005 (trehalose), Lysogene (LYS-SAF302), Tralesinidase alfa (BMN 250) and others will add to the Sanfilippo syndrome market size.

Market Restraints

The difficulty of the administered drugs in crossing the blood-brain barrier and the death of neurons in MPS-III acts as a restraint. Limited patient populations, difficulties in diagnosis, and high costs associated with research and development also act as market growth restraints.

Key players

uniQure Ionis Pharmaceuticals Alnylam Pharmaceuticals Pfizer Sanofi Shire plc BioMarin Pharmaceutical Inc. Orchard Therapeutics plc PTC Therapeutics Inc. Novartis

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Australia MPS-III (Sanfilippo Syndrome) drugs market

By Target

Alpha N-Acetylglucosaminidase
N Sulphoglucosamine Sulphohydrolase
Polyadenylate Binding Protein 2
Heparan Alpha Glucosaminide N-Acetyltransferase
Interleukin 1 Receptor Type 1
N-Acetylgalactosamine 6 Sulfatase

By Treatment type

Gene therapy
Recombinant enzyme
Fusion protein
Gene-modified cell therapy
Small Molecule
Enzyme

By Route of administration

Intravenous
Intrathecal
Intracerebral
Nasal
Oral

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.